Denizot Y - Search Results

1

Lipid mediators and human leukemic blasts.

Fiancette R, Vincent-Fabert C, Guerin E, Trimoreau F, Denizot Y. Fiancette R, et al. Among authors: denizot y. J Oncol. 2011;2011:389021. doi: 10.1155/2011/389021. Epub 2010 Oct 10. J Oncol. 2011. PMID: 20953410 Free PMC article.

2

5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts.

Vincent C, Fiancette R, Donnard M, Bordessoule D, Turlure P, Trimoreau F, Denizot Y. Vincent C, et al. Among authors: denizot y. Leuk Res. 2008 Nov;32(11):1756-62. doi: 10.1016/j.leukres.2008.05.005. Epub 2008 Jun 18. Leuk Res. 2008. PMID: 18561999

3

PGE(2) receptor subtype functionality on immature forms of human leukemic blasts.

Malissein E, Reynaud S, Bordessoule D, Faucher JL, Turlure P, Trimoreau F, Denizot Y. Malissein E, et al. Among authors: denizot y. Leuk Res. 2006 Oct;30(10):1309-13. doi: 10.1016/j.leukres.2005.12.017. Epub 2006 Feb 7. Leuk Res. 2006. PMID: 16460799

4

Functional platelet-activating factor receptors in immature forms of leukemic blasts.

Reynaud S, Malissein E, Donnard M, Bordessoule D, Turlure P, Trimoreau F, Denizot Y. Reynaud S, et al. Among authors: denizot y. Leuk Res. 2007 Mar;31(3):399-402. doi: 10.1016/j.leukres.2006.06.002. Epub 2006 Jul 11. Leuk Res. 2007. PMID: 16837045

5

Effects of lipid mediators on the synthesis of leukaemia inhibitory factor and interleukin 6 by human bone marrow stromal cells.

Denizot Y, Trimoreau F, Praloran V. Denizot Y, et al. Cytokine. 1998 Oct;10(10):781-5. doi: 10.1006/cyto.1998.0360. Cytokine. 1998. PMID: 9811531

6

Lipid mediators modulate the synthesis of interleukin 8 by human bone marrow stromal cells.

Denizot Y, Godard A, Raher S, Trimoreau F, Praloran V. Denizot Y, et al. Cytokine. 1999 Aug;11(8):606-10. doi: 10.1006/cyto.1998.0467. Cytokine. 1999. PMID: 10433808

7

Platelet-activating factor and normal or leukaemic haematopoiesis.

Denizot Y, Guglielmi L, Donnard M, Trimoreau F. Denizot Y, et al. Leuk Lymphoma. 2003 May;44(5):775-82. doi: 10.1080/1042819031000067549. Leuk Lymphoma. 2003. PMID: 12802913 Review.

8

Ig synthesis and class switching do not require the presence of the hs4 enhancer in the 3' IgH regulatory region.

Vincent-Fabert C, Truffinet V, Fiancette R, Cogné N, Cogné M, Denizot Y. Vincent-Fabert C, et al. Among authors: denizot y. J Immunol. 2009 Jun 1;182(11):6926-32. doi: 10.4049/jimmunol.0900214. J Immunol. 2009. PMID: 19454689

9

A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.

Fiancette R, Amin R, Truffinet V, Vincent-Fabert C, Cogné N, Cogné M, Denizot Y. Fiancette R, et al. Among authors: denizot y. Leuk Res. 2010 Aug;34(8):1043-51. doi: 10.1016/j.leukres.2009.11.017. Leuk Res. 2010. PMID: 20018375

10

Genomic deletion of the whole IgH 3' regulatory region (hs3a, hs1,2, hs3b, and hs4) dramatically affects class switch recombination and Ig secretion to all isotypes.

Vincent-Fabert C, Fiancette R, Pinaud E, Truffinet V, Cogné N, Cogné M, Denizot Y. Vincent-Fabert C, et al. Among authors: denizot y. Blood. 2010 Sep 16;116(11):1895-8. doi: 10.1182/blood-2010-01-264689. Epub 2010 Jun 10. Blood. 2010. PMID: 20538806 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

234 results

Search Page